Mode
Text Size
Log in / Sign up

Protocol for randomized controlled trial of TEAS pretreatment for breast cancer-related lymphedemaNew electrical therapy may stop breast cancer swelling before surgery starts

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that no efficacy or safety data are reported as this study remains a protocol.

This randomized controlled trial protocol describes a planned study involving 72 breast cancer participants scheduled for axillary lymph node dissection. The research will be conducted at Yunnan Provincial Hospital of Traditional Chinese Medicine and the First Affiliated Hospital of Kunming Medical University. The primary objective is to evaluate the incidence and time of onset of lymphedema within 18-month postoperatively. The follow-up duration is set at 18-month.

Participants will receive transcutaneous electrical acupoint stimulation pretreatment or sham TEAS. Secondary outcomes include VAS scores for perceived swelling, changes in circumference, edema stage, and severity of the affected limb. Additional assessments involve skin thickness ultrasound, lymphangiography of the affected limb, and serum inflammatory factor levels.

No main results are reported because the study is currently a protocol. Adverse events occurring during the trial will be recorded, but serious adverse events and discontinuations are not reported. Tolerability data are also not reported. The certainty of findings is limited as no efficacy or safety data exist yet. Funding and conflicts of interest are not reported.

If effective, TEAS will become a non-invasive adjunct therapy for preventing BCRL. However, practice relevance remains uncertain until results are published. Clinicians must recognize that prevention claims cannot be made based on this protocol alone.

Arm swelling after breast cancer surgery is a heavy burden. It changes how a woman moves and feels in her daily life. Many women fear this outcome before they even step into the operating room.

Breast cancer-related lymphedema is a serious complication. It happens when lymph nodes are removed during surgery. The body loses its drainage system for fluid. This causes fluid to build up in the arm or chest wall.

Doctors have tried many treatments to fix this problem. Some involve compression sleeves and manual massage. Others use special exercises to move fluid around. But prevention is often the hardest part to solve.

But here is the twist. A new method called transcutaneous electrical acupoint stimulation might change the game. This technique uses gentle electricity to nudge the body into action. It is a non-invasive way to help the lymph system work better.

Think of the lymph system like a busy highway. Cars are the fluid that needs to move. Sometimes traffic jams happen because of road construction or accidents. Surgery is like a major construction project. It blocks the road and causes backups.

TEAS acts like a traffic cop. It sends signals to the cells that move fluid. These signals tell the cells to work harder. They open up pathways and clear the blockage. This analogy helps explain how a small electrical pulse can have a big effect.

The study will look at 72 women scheduled for surgery. They will come from two hospitals in China. Half will get the real electrical treatment. The other half will get a fake version that feels the same but does nothing.

Treatment starts before the knife ever touches the skin. It happens once a day for three days before surgery. Then it pauses on the day of the operation. Afterward, patients get it twice a week for four weeks. This totals twelve sessions of care.

The main goal is to see if swelling happens at all. Doctors will track the arm for eighteen months after surgery. They will measure how big the arm gets and how long it takes for swelling to start.

They will also check how the patient feels. Pain and discomfort are important parts of the picture. Ultrasound scans will show if the skin gets thicker. Blood tests will check for inflammation markers in the body.

This does not mean this treatment is available yet. The study is still in its planning phase. Researchers need to prove it works safely in real life. They must also show it is better than doing nothing.

Experts say prevention is better than cure. If this therapy works, it could be added to standard care. It would give doctors a new tool to fight swelling. It would also give patients peace of mind before their big day.

However, there is a catch. The study is happening in China. Results from one country might not match another. Different people have different genetics and lifestyles. This means doctors will need to test it locally before using it widely.

The study team knows the risks of rushing. They want to gather high-quality data first. This takes time and careful planning. They will record any side effects that happen during the trial. Safety is just as important as effectiveness.

What happens next depends on the results. If the data looks good, the therapy could get approved. It might become a standard part of breast cancer care. Patients would get this help before they even enter the hospital.

If the results are mixed, the team will look for reasons. Maybe the electricity needs to be stronger. Or maybe the timing needs to change. Science is a process of trial and error.

Research takes time because health is too important to rush. We need to be sure a new treatment helps more than it hurts. This study follows that rule carefully. It will provide clear answers for doctors and patients alike.

The road ahead is long but promising. New tools for lymphedema care are needed. This electrical therapy offers a fresh approach. It could finally solve a problem that has plagued patients for years.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
IntroductionBreast cancer-related lymphedema (BCRL) is a serious and intractable complication that severely affects the quality of life and survival rates of cancer patients. Transcutaneous electrical acupoint stimulation (TEAS) has been applied in China for the treatment of lymphedema. However, there is currently no high-quality evidence-based data confirming the efficacy, safety, and preventive therapeutic role of TEAS for BCRL. This study aims to evaluate the efficacy and safety of TEAS pretreatment for BCRL through a multicenter, prospective, randomized, sham-controlled, parallel-group clinical trial, thereby providing evidence-based medical evidence.Methods and analysisA total of 72 breast cancer participants scheduled for axillary lymph node dissection will be recruited from Yunnan Provincial Hospital of Traditional Chinese Medicine and the First Affiliated Hospital of Kunming Medical University. They will randomly assigned in a 1:1 ratio to the TEAS group or the Sham TEAS group, with 36 cases in each group. Treatment will be administered once daily from the first day before surgery to the third day after surgery (paused on the surgery day), and subsequently twice a week for 4 consecutive weeks, totaling 12 intervention sessions. This will be followed by an 18-month follow-up period. The primary outcome measures are the incidence and time of onset of lymphedema within 18-month postoperatively. Secondary outcome measures include: VAS scores for perceived swelling and lymphedema-related symptoms evaluated at baseline (T0), from preoperative to postoperative day 3 (T1-T4), upon completion of twice-weekly post-discharge treatments (T5-T12), and during monthly follow-ups until 18 months postoperatively (T13-T29); changes in circumference, edema stage, and severity of the affected limb evaluated at T0, before and after treatments from preoperative to postoperative day 3 (T1a/b-T4a/b), before and after twice-weekly post-discharge treatments (T5a/b-T12a/b), and at T29; skin thickness ultrasound and lymphangiography of the affected limb performed at T0, T2, T12, and T29; and serum inflammatory factor levels measured at T0, T4, and T12. Adverse events occurring during the trial will be recorded.DiscussionThis study aims to evaluate the efficacy and safety of TEAS pretreatment for BCRL. If effective, TEAS will become a non-invasive adjunct therapy for preventing BCRL.Clinical trial registrationChinese Clinical Trial Registry [website], identifier ChiCTR2400088117.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.